Toxicology and Safety Pharmacology of Quinolones

  • E. Von Keutz
  • W. Christ
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 127)


Quinolones have proven to be valuable drugs with interesting microbiological, pharmacokinetic, and therapeutic properties. The aim of this article is to give an overview of the toxicological profile of this class of compounds. Based on current knowledge, it appears that the pattern of preclinical adverse reactions is comparable for all quinolones, although there are some differences in both the incidence and the type of reaction induced by certain compounds. The published toxicological profile for the quinolones (Table 1) includes arthropathy, Achilles tendinitis and rupture, nephropathy, effects on the central nervous system (CNS), ocular toxicity, impairment of spermatogenesis, cardiovascular effects, possible mutagenic and carcinogenic effects, phototoxicity, photocarcinogenicity, photomutagenicity, drug interactions, and metabolic and nutritional events. The aim of this paper is to review and discuss the data derived from animal toxicology studies of the effects of quinolones at these target sites.


Nalidixic Acid Antimicrob Agent Oxolinic Acid Pipemidic Acid Safety Pharmacology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akahane K, Sekiguchi M, Une T, Osada Y (1989) Structure relationship of quinolones with special reference to their interaction with 7-aminobutyric acid receptor sites. Antimicrob Agents Chemother 33:1704–1708PubMedGoogle Scholar
  2. Akaike N, Shirasaki T, Yakushiji T (1989) Quinolones and fenbufen interact with GABA A receptors in dissociated hippocampal cells of rat. J Neurophysiol 66:497- 504Google Scholar
  3. Albertini S, Chetelat AA, Miller B, Muster W, Pujadas E, Strobel R, Gocke E (1995) Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic cell systems. Mutagenesis 10(4):343–351PubMedCrossRefGoogle Scholar
  4. Alzheimer C, Röhrenbeck J, ten Bruggencate G (1991) Adenosine depressed induction of LTP at the mossy-fiber-CA3 synapse in vitro. Brain Res 543:163–165PubMedCrossRefGoogle Scholar
  5. Anderson RD, Berger NA (1994) Mutagenicity and carcinogenicity of topoisomerase- interactive agents. Mutat Res 309:109–142PubMedCrossRefGoogle Scholar
  6. Anonymous (1988) Pefloxacin. Rhone-Poulenc, Antony, France (Product monograph)Google Scholar
  7. Bailey RR, Peddie BA (1985) Enoxacin for the treatment of urinary tract infection. N Z Med J 98:268–288Google Scholar
  8. Bailey RR, Kirk JA, Peddie BA (1983) Norfloxacin-induced rheumatic disease. N Z Med J 96:590PubMedGoogle Scholar
  9. Baraban JM, Cole AJ, Stratton KR, Pritchett J, Alvaro J, Abushakra S, Saffen DW, Worley PF (1991) Neuronal excitability: focus on second messenger systems. In: Fischer RS, Coyle JT (eds) Neurotransmitters and epilepsy. Wiley-Liss, New York, pp 35–37Google Scholar
  10. Barrett JF, Gootz TD, McGuirk PR, Farrell CA, Sokolowski SA (1989) Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother 33:1697–1703PubMedGoogle Scholar
  11. Bredberg A, Brant M, Riesbeck K, Azou Y, Forsgren A (1989) 4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction. Mutat Res 211:171–180Google Scholar
  12. Brendler-Schwaab SY, Herbold BA (1995) BAY y 3118: a photomutagenic quinolone. 7th Congress of Toxicology, July 2–6, SeattleGoogle Scholar
  13. Brendler-Schwaab SY, von Keutz E, Schlüter G, Herbold BA (1995) A new approach to screen for photomutagenicity with the HPRT-assay. Workshop “Pho- tocarcinogenesis: Mechanisms, Models and Human Health Implications”, Oct 27–28, WashingtonGoogle Scholar
  14. Burkhardt JE, Hill MA, Lamar CH, Smith GN, Carlton WW (1993) Effects of difloxacin on the metabolism of glycosamino-glycans and collagen in organ cultures of articular cartilage. Fundam Appl Toxicol 20:257–263PubMedCrossRefGoogle Scholar
  15. Carlin H (1975) Pharmacology review of cinoxacin. Food and Drug Administration, RockvilleGoogle Scholar
  16. Chételat A, Albertini S, Gocke E (1995) Photogenotoxicity of fluoroquinolone antibiotics. Workshop “Photocarcinogenesis: Mechanisms, Models and Human Health Implications”, Oct 27–28, WashingtonGoogle Scholar
  17. Christ W (1990) Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 26(B):219–225PubMedGoogle Scholar
  18. Christ W, Esch B (1994) Adverse reactions to fluoroquinolones in adults and children. Infect Dis Clin Pract 3(3):168–176CrossRefGoogle Scholar
  19. Christ W, Lehnert T (1990) Toxicity of the quinolones. In: Siporin C, Heifetz CL, Domagala JM (eds) The new generation of quinolones. Dekker, New York, pp 165–186Google Scholar
  20. Christ W, Gindler K, Gruene S, Hecker W, Jacobsen M, Junge H, Park H-H (1988a) Interactions of quinolones with opioids and fenbufen, a nonsteroidal antiinflammatory drug: involvement of dopaminergic neurotransmission. Rev Infect Dis 11(5):1393–1394Google Scholar
  21. Christ W, Lehnert T, Ulbrich B (1988b) Specific toxicologic aspects of the quinolones. Rev Infect Dis 10:141–146CrossRefGoogle Scholar
  22. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R (1991) Safety of ciprofloxacin in children: worldwide experience based on compassionate use. Emphasis on joint evaluation. Infection 19:289–296PubMedCrossRefGoogle Scholar
  23. Ciavarino V, Suto MJ, Theis JC (1993) High capacity in vitro micronucleus assay for assessment of chromosomal damage: results with quinolone/naphthyridone anti- bacterials. Mutat Res 298:227–236CrossRefGoogle Scholar
  24. Clerch B, Barbé J, Llagostera M (1992) The role of the excision and error-prone repair systems in mutagenesis by fluorinated quinolones in Salmonella typhimurium. Mutat Res 281:207–213PubMedCrossRefGoogle Scholar
  25. Cohen A, Rosenberg F (1992) Trois nouveaux de tendiopathie achilléenne après traitement par fluoroquinolones (Abstr). Rev Rhum Mal Osteoartic 59:E23Google Scholar
  26. Cullmann W, Geddes AM, Weidekamm E, Urwyler H, Braunsteiner A (1993) Fleroxacin: a review of its chemistry, microbiology, toxicology, pharmacokinetics, clinical efficacy and safety. Int J Antimicrob Agents 2:203–230PubMedCrossRefGoogle Scholar
  27. Dalhoff A (1989) In: Fernandes PB (ed) Quinolones. A review of quinolone tissue pharmacokinetics. Praus, pp 277–312Google Scholar
  28. Davey PG (1988) Overview of drug interactions with the quinolones. J Antimicrob Chemother 22C97–107CrossRefGoogle Scholar
  29. Davies BI, Maesen FPV (1989) Drug interactions with quinolones. Rev Infect Dis 11(5):1083–1090CrossRefGoogle Scholar
  30. De Sarro A, Ammendola D, De Sarro G (1994) Effects of some quinolones on imipenem-induced seizures in DBA/2 mice. Gen Pharmacol 25:369–379PubMedCrossRefGoogle Scholar
  31. Dimpfel W, Spüler M, Dalhoff A, Hofmann W, Schlüter G (1991) Hippocampal activity in the presence of quinolones and fenbufen in vitro. Antimicrob Agents Chemother 35:1142–1146PubMedGoogle Scholar
  32. Dimpfel W, Dalhoff A, Hofmann W, Schlüter G (1994) Electrically evoked potentials in the rat hippocampus slice in the presence of aminophylline alone and in combination with quinolones. Eur Neuropsychopharmacol 4:151–156PubMedCrossRefGoogle Scholar
  33. Dimpfel W, Dalhoff A, von Keutz E (1995) In vitro modulation of hippocampal pyramidal cell response by quinolones. Effect of HA 966 and γ-hydroxybutyric acid J Antimicrob Chemother 40(ll):2573–2576Google Scholar
  34. Dodd PR, Davies LP, Watson WEJ, Nielsen B, Deyer JA, Wong LS, Johnston GAR (1989) Neurochemical studies on quinolone antibiotics: effects on glutamate, GABA and adenosine systems in mammalian CNS. Pharmacol Toxicol 64:404- 411PubMedCrossRefGoogle Scholar
  35. Domagala JM (1994) Structure-activity and structure-side-effect relationship for the quinolone antibacterials. J Antimicrob Chemother 33:685–706PubMedCrossRefGoogle Scholar
  36. Drlica K, Franco RJ (1988) Inhibitors of DNA topoisomerase. Biochemistry 27:2253- 2259PubMedCrossRefGoogle Scholar
  37. Edwards DJ, Bowles SK, Svensson CK, Rybak MJ (1988) Inhibition of drug metabolism by quinolone antibiotics. Clin Pharmacokinet 15:194–204PubMedCrossRefGoogle Scholar
  38. Elsea SH, Osheroff N, Nitiss JL (1992) Cytotoxicity of quinolones towards eukaryotic cells. J Biol Chem 267(19):13150–13153PubMedGoogle Scholar
  39. Ferguson LR, Baguley BC (1994) Review article: topoisomerase II enzymes and mutagenicity. Environ Mol Mutagen 24:245–261PubMedCrossRefGoogle Scholar
  40. Forbes PD, Sambuca CP, Arocena MA, D’Aloisio LC, Hoberman AM (1995) Fluoroquinolone antibiotics (FQA) induce photosensitized skin reactions in hairless mice exposed to simulated sunlight (Abstr 1712). Toxicologist 15:319Google Scholar
  41. Fort FL (1992) Mutagenicity of quinolone antibacterials. Drug Saf 7:214–222PubMedCrossRefGoogle Scholar
  42. Franck JL, Bouteiller G, Chagnaud P, Sapene M, Gautier D (1991) Rupture des tendons d’achille chez deux adultes traités par péfloxacine dont un cas bilatéral. Rev Rhum Mal Osteoartic 58:904PubMedGoogle Scholar
  43. Gootz TD, Barrett JF, Sutcliffe JA (1990) Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems. Antimicrob Agents Chemother 34:8–12PubMedGoogle Scholar
  44. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, De la Iglesia FA (1979) Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipedimic acids. Toxicol Appl Pharmacol 51:177–187PubMedCrossRefGoogle Scholar
  45. Halliwell RF, Labert JJ, Davey PG (1989) Actions of quinolones and nonsteroidal antiinflammatory drugs on y-aminobutyric acid currents of rat dorsal root ganglion neurons. Rev Infect Dis 11(5):1398–1399Google Scholar
  46. Halliwell RF, Davey PG, Lambert JJ (1991) The effect of quinolones and NSAIDs upon GABA-evoked currents recorded from dorsal root ganglia neurons. J Antimicrob Chemother 27:209–218PubMedCrossRefGoogle Scholar
  47. Halliwell RF, Davey PG, Lambert JJ (1993) Antagonism of GABA a receptors by 4- quinolones. J Antimicrob Chemother 31:457–462PubMedCrossRefGoogle Scholar
  48. Herbold BA, Gahlmann R, Schlüter G (1995) Ciprofloxacin, a potent gyrase inhibitor: Studies on genotoxicity. Mutat Res (in press)Google Scholar
  49. Hildebrand H, Kempka G, Schlüter G, Schmidt M (1993) Chondrotoxicity of quinolones in vivo and in vitro. Arch Toxicol 67:411–415PubMedCrossRefGoogle Scholar
  50. Hori S, Shimada J (1993) Effects of quinolones on the central nervous system. In: Hooper DC, Wolfson JS (eds) Quinolone antimicrobial agents, 2nd edn. American Society for Microbiology, WashingtonGoogle Scholar
  51. Hori S, Shimada J, Saito A, Miyahara T, Kurioka S, Matasuda M (1987a) A study on enhanced epileptogenicity of new quinolones in the presence of antiinflammatory drugs (Abstr 30). 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, Oct 4–7, New York. American Society for Microbioloy, Washington, p 101Google Scholar
  52. Hori S, Shimada J, Saito A, Matsuda M, Miyahara T (1987b) Comparison of the inhibitory effects of new quinolones on γ-aminobutyric acid receptor binding in the presence of antiinflammatory drugs. Rev Infect Dis 11(5):1397–1398Google Scholar
  53. Horio T, Miyauchi H, Asada Y, Aoki Y, Harada M (1994) Phototoxicity and photoallergenicity of quinolones in guinea pigs. J Dermatol Sci 7(2):130–135PubMedCrossRefGoogle Scholar
  54. Hosomi J, Maeda A, Oomori Y, Irikura T, Yokota T (1988) Mutagenicity of norfloxacin and AM-833 in bacteria and mammalian cells. Rev Infect Dis 10(1):148–149Google Scholar
  55. Hussy P, Maass G, Tümmler BL, Grosse FL, Schomburg U (1986) Effect of 4- quinolones and novobiocin on calf thymus DNA polymerase a primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother 29:1073–1078PubMedGoogle Scholar
  56. Ichikawa N, Naora K, Hayashibara M (1992) Effect of fenbufen on the entry of new quinolones, norfloxacin and ofloxacin, into the central nervous system in rats. J Pharm Pharmacol 44:915–920PubMedCrossRefGoogle Scholar
  57. Iida M, Yasuba M, Nakajima F, Maeda T, Matsuoka N, Ohnishi K (1991) Four week oral subacute toxicity study of Sparfloxacin in beagle dogs. Chemotherapy (Tokyo) 39(4): 195–202Google Scholar
  58. Ingham B, Brentnall DW, Dale EA, McFadzean JA (1977) Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1:21–26CrossRefGoogle Scholar
  59. Irikura T, Suzuki H, Sugimoto T (1981) Mutagenicity studies of AM-715 in animals. Chemotherapy (Tokyo) 29(4):932–937Google Scholar
  60. Iwamoto K, Naora K, Katagiri Y, Ichigawa N, Hayashibara M, Tanaka K, Yamaguchi T, Sekine Y (1993) Comparative neurotoxicity study of ciprofloxacin and Sparfloxacin after coadministration with fenbufen in rats. Drugs 45(3):290–291CrossRefGoogle Scholar
  61. Jaehde U, Goto T, de Boer AG, Breimer DD (1993) Blood-brain transport rate of quinolone antibacterials evaluated in cerebrovascular endothelial cell cultures. Eur J Pharm Sci 1:49–55CrossRefGoogle Scholar
  62. Janknegt R (1990) Drug interactions with quinolones. J Antimicrob Chemother 26(D):7–29PubMedGoogle Scholar
  63. Johnson BE, Walker EM, Ferguson J (1989) Quinolone-induced photosensitivity. Rev Infect Dis 11(5):1396–1397Google Scholar
  64. Jorgensen C, Anaya JM, Didry C, Canovas F, Serre I, Baldet P, Ribard P, Kahn MF, Sany J (1991) Arthropathies et tendinopathie achilleenne induites par la pefloxacine. A propos d’une observation. Rev Rhum Mai Osteoartic 58:623–625Google Scholar
  65. Kahn MF, Carbon C (1993) Tendinopathies et fluoroquinolones. Concours Med 115:819–823Google Scholar
  66. Kajimura T, Tojo H, Kudo G, Yamada M, Domon S, Nomura M, Takayama S (1992) Effect of the new quinolone antibacterial agent levofloxacin on multiple organ carcinogenesis initiated with wide-spectrum carcinogens in rats. Arzneimittelforschung 42(3a):390–395Google Scholar
  67. Kato M, Onodera T (1988) Morphological investigation of cavity formation in articular cartilage induced by ofloxacin in rats. Fundam Appl Toxicol 11:110–119PubMedCrossRefGoogle Scholar
  68. Kato M, Takada S, Kashida Y, Nomura M (1995) Histological examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol Pathol 23(3):385–392PubMedCrossRefGoogle Scholar
  69. Kempka G, Ahr HJ, Rüther W, Schlüter G (1996). The effects of fluoroquinolones and glucocorticoids on cultivated tendon cells in vitro. Toxicol In Vitro 10:743–754PubMedCrossRefGoogle Scholar
  70. Lomaestro BM, Bailie GR (1991) Quinolone-cation interactions: a review. DICP Ann Pharmacother 25:1249–1258Google Scholar
  71. Marchese AL, Slana VS, Holmes EW, Jay WM (1993) Toxicity and pharmacokinetics of ciprofloxacin. J Ocul Pharmacol 9(1):69–76PubMedCrossRefGoogle Scholar
  72. Marutani K, Matsumoto M, Otabe Y et al (1993) Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob Agents Chemother 37:2217–2223PubMedGoogle Scholar
  73. Matsumoto M, Kojima K, Nagano H, Matsubara S, Yokota T (1992) Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV- irridation. Antimicrob Agents Chemother 36:1715–1719PubMedGoogle Scholar
  74. Mayer DG (1987) Overview of toxicological studies (ofloxacin). Drugs 34(1):150–153PubMedCrossRefGoogle Scholar
  75. McEwan SR, Davey PG (1988) Ciprofloxacin and tendosynovitis. Lancet 2:900PubMedCrossRefGoogle Scholar
  76. McQueen CA, Way BM, Queener SM, Schlüter G, Williams GM (1991) Study of potential in vitro and in vivo genotoxicity in hepatocytes of quinolone antibiotics. Toxicol Appl Pharmacol 111:255–262PubMedCrossRefGoogle Scholar
  77. Mitelman F, Kolnig A-M, Strömbeck B, Norrby R, Kromann-Andersen B, Sommer P, Wadstein J (1988) No cytogenetic effects of quinolone treatment in humans. Antimicrob Agents Chemother 32:936–937PubMedGoogle Scholar
  78. Mitsui Y (1992) Pharmacological characteristics of fluoroquinolones. J Eye 9(2):215- 223Google Scholar
  79. Mochzuki K, Torisaki M, Wakabayashi K (1991) Effects of vancomycin and ofloxacin on rabbit — ERG in vivo. Jpn J Ophthalmol 35(4):435–445Google Scholar
  80. Morikawa K, Nagata O, Kubo S, Kato H (1987) Unusual CNS toxic action of new quinolones. 27th Interscience Conference of Antimicrobial Agents and Chemotherapy, October 4–7, New York. American Society for Microbiology, WashingtonGoogle Scholar
  81. Morrissey ER, Eustis S, Haseman JK, Huff J, Bucher JR (1991) Toxicity and carcinogenicity studies of nalidixic acid in rodents. Drug Chem Toxicol 14:45–66PubMedCrossRefGoogle Scholar
  82. Nix DE, De Vito JM, Whitbread MA, Schentag JJ (1987) Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J Antimicrob Chemother 19:263–269PubMedCrossRefGoogle Scholar
  83. Nomura M, Yamada M, Yamamura H, Kajimura T, Takayama S (1992) Ophthalmotoxicity and ototoxicity of the new quinolone antibacterial agent levofloxacin in long evans rats. Arzneimittelforschung 42(3A):398–403Google Scholar
  84. Nozaki M, Takeda N, Tanaka K, Tsurumi K (1989) GABA-ergic mechanism on convulsions induced by combination with new quinolones and NSAIDs; true or not. 16th International Congress of Chemotherapy, JerusalemGoogle Scholar
  85. Oomomo A (1991) Intravitreal injection of norfloxacin or ofloxacin. II Retinal toxicity (in Japanese). Atarashii Ganka 8(4):651–654Google Scholar
  86. Oomori Y, Yasue T, Aoyama H, Hirai K, Suzue S, Yokota T (1988) Effects of fleroxacin on HeLa cell functions and topoisomerase II. J Antimicrob Chemother 22(D):91–97PubMedGoogle Scholar
  87. Osheroff N, Elsea SH, Nitiss JL (1992) Cytotoxicity of quinolones towards eukaryotic cells. J Biol Chem 267:13150–13153PubMedGoogle Scholar
  88. Paton JH, Reeves DS (1991) Clinical features and management of adverse effects of quinolone antibacterials. Drug Saf 6:8–27PubMedCrossRefGoogle Scholar
  89. Paton JH, Reeves DS (1992) Adverse reactions to the fluoroquinolones. Adverse Drug React Bull 153:575–578CrossRefGoogle Scholar
  90. Percival A (1991) Impact of chemical structure on quinolone potency, spectrum and side effects. J Antimicrob Chemother 28(C):1–8PubMedCrossRefGoogle Scholar
  91. Perrot S, de Bourran-Cauet G, Lanchand AT, Desplaces N, Kaplan G, Ziza JM (1991) Nouvelle complication liee aux quinolones: la rupture du tendon d’achille (Abstr). Rev Rhum Mai Osteoartic 58:125Google Scholar
  92. Polk RE (1989) Drug-drug interactions with ciprofloxacin and other fluoroquinolones. AM J Med 87(5A):5A–76SGoogle Scholar
  93. Przbilla B, Georgii A, Bergner T, Ring J (1990) Demonstration of quinolone phototoxicity in vitro. Dermatology 181:98–103CrossRefGoogle Scholar
  94. Psarropoulou C, Kostopoulos G (1990) Long-term potentiation of postsynaptic excitability after brief exposure to Mg++-free medium in normal and epileptic mice. Brain Res 508:70–75PubMedCrossRefGoogle Scholar
  95. Raasch W, Grobecker H, Kees F (1992) Influence of ciprofloxacin on brain metabolism of biogenic amines in the rat. Pharm Pharmamacol Lett 2:153–156Google Scholar
  96. Ribard P, Kahn MF (1991) Rheumatological side-effects of quinolones. Baillieres Clin Rheumatol 15:175–191CrossRefGoogle Scholar
  97. Ribard P, Audisio F, DeBandt M, Kahn MF, Palazzo E, Meyer O (1991) 5 cas de tendinite d’achille, dont 2 avec rupture, au cours de traitememts par les fluoroquinolones (Abstr). Rev Rhum Mai Osteoartic 58:126Google Scholar
  98. Ribard P, Audisio F, Kahn MF, DeBandt M, Jorgensen C, Hayem G, Meyer O, Palazzo E (1992) Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J Rheumatol 19:1479–1481PubMedGoogle Scholar
  99. Robertson DG, Epling GA, Kiely JS, Bailey DL, Song B (1991) Mechanistic studies of the phototoxic potential of PD 117595, a quinolone antibacterial compound. Toxicol Appl Pharmacol 111:221–232PubMedCrossRefGoogle Scholar
  100. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N (1991) Effects of quinolone derivative on eukaryotic topoisomerase II. J Biol Chem 266:14585–14592PubMedGoogle Scholar
  101. Rose TF, Bremner DA, Collins J, Ellis-Pegler R, Isaaca R, Richardson R, Small M (1990) Plasma and dialysate levels of pefloxacin and its metabolites in CAPD patients with peritonitis. J Antimicrob Chemother 25:657–664PubMedCrossRefGoogle Scholar
  102. Rosen JE, Prahalad AK, Williams GM (1995) Quinolone antibacterial phototoxicity as measured by oxidative DNA damage (Abstr 157). Toxicologist 15:29Google Scholar
  103. Royer RJ, Pierfitte C, Netter P (1994) Features of tendon disorders with fluoroquinolones. Therapie 49:75–76PubMedGoogle Scholar
  104. Schaad UB, Wedgwood J (1992) Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother 30:414–416PubMedCrossRefGoogle Scholar
  105. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P (1991) Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 10:723–729PubMedGoogle Scholar
  106. Schlüter G (1987a) Toxicology of quinolones. In: Naber KG, Adam D, Grobecker H (eds) Gyrase-Hemmer II. FAC (Fortschritte der antimikrobiellen und antine- oplastischen Chemotherapie), vol 6–10. Futuramed, Munich, pp 1631–1642Google Scholar
  107. Schlüter G (1987b) Ciprofloxacin: review of potential toxicologic effects. Am J Med 82(4A):91–96Google Scholar
  108. Schürmann A (1995) Potentielle neurotoxische Wirkung von Chinolonen im zentralen Nervensystem. PhD thesis, Ruhr Universit, BochumGoogle Scholar
  109. Shimada H, Yutaka E, Kurusawa Y, Arauchi T (1984) Mutagenicity studies of DL- 8280, a new antibacterial drug. Chemotherapy (Tokyo) 32(1):1162–1170Google Scholar
  110. Shimada H, Itoh S, Hattori C, Tada S, Matsuura Y (1992) Mutagenicity of the new quinolone antibacterial agent levofloxacin. Arzneimittelforschung 42(3A):378- 385Google Scholar
  111. Shimoda K, Yoshida M, Wagai N, Takayama S, Kato M (1993) Phototoxic lesions induced by quinolone antibacterial agents in auricular skin and retina of albino mice. Toxicol Pathol 21(6):554–561PubMedCrossRefGoogle Scholar
  112. Shirasaki T, Harata N, Nakaye T, Akaike N (1991) Interaction of various non-steroidal antiinflammatories and quinolone antimicrobials on GAB A response in rat dissociated hippocampal pyramidal neurons. Brain Res 562:329–331PubMedCrossRefGoogle Scholar
  113. Shiratori O, Takase S (1980) Mutagenic activity tests on cinoxacin in vitro and in vivo cytogenetic tests in mammalian cells. Chemotherapy (Tokyo) 28(4):523–529Google Scholar
  114. Siefert HM, Maruhn D, Maul W, Förster D, Ritter W (1986a) Pharmacokinetics of ciprofloxacin, 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C] ciprofloxacin in albino rats and rhesus monkeys. Arzneimittelforschung 36:1496–1502PubMedGoogle Scholar
  115. Siefert HM, Maruhn D, Scholl H (1986b) Pharmacokinetics of ciprofloxacin, 2nd communication: distribution to and elimination from tissues and organs following single or repeated administration of [14C]ciprofloxacin in albino rats. Arzneimittelforschung 36:1503–1510PubMedGoogle Scholar
  116. Stahlmann R (1990) Safety profile of the quinolones. J Antimicrob Chemother 26(D):31–44PubMedGoogle Scholar
  117. Stahlmann R, Merker HJ, Hinz N, Chahoud I, Webb J, Heger W, Neubert D (1990) Ofloxacin in juvenile, non-human primates and rats. Arthropathia and drug plasma concentrations. Arch Toxicol 64:193–204PubMedCrossRefGoogle Scholar
  118. Stahlmann R, Förster C, Shakibaei M (1993a) Decrease of ß 1-integrins in cartilage from juvenile rats after ofloxacin treatment. Naunyn Schmiedebergs Arch Pharmacol 348(Suppl):R170Google Scholar
  119. Stahlmann R, Förster C, Van Sickle D (1993b) Quinolones in children. Are concerns over arthropathy justified? Drug Saf 9:397–403PubMedCrossRefGoogle Scholar
  120. Stahlmann R, Förster C, Shakibaei M, Vormann J, Stürje H (1995) Ofloxacin-induced joint cartilage lesions in immature rats are identical with lesions induced by magnesium-deficient diet (Abstr. 888). Toxicologist 15:167Google Scholar
  121. Sutcliffe JA, Osheroff N (1991) Effects of quinolone derivatives on eukaryotic topoisomerase. II. J Biol Chem 266:14585–14592PubMedGoogle Scholar
  122. Suzuki H, Takahashi T, Sato Y, Abe Y (1990) Fertility study on fleroxacin in rats. Chemotherapy (Tokyo) 38(2):261–271Google Scholar
  123. Takayama S, Hirohashi M, Kato M, Shimada H (1995) Toxicity of the quinolone antimicrobial agents (review). J Toxicol Environ Health 45:1–45PubMedCrossRefGoogle Scholar
  124. Tanahashi T, Mochizuki K, Torisaki M, Yamashita Y, Komatsu M, Higashide T, Ogata M (1992) Effect of intravitreal injection of norfloxacin on the retina in pigmented rabbits. Lens Eye Toxicol Res 9(3–4):493–503Google Scholar
  125. Tatsumi H, Senda H, Yatera S, Takemoto Y, Yamoyoshi M, Ohnishi K (1978) Toxico- logical studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci 3:357–367PubMedCrossRefGoogle Scholar
  126. Terada Y, Aoki Y, Mukumoto K, Shigematsu K, Nishimura K, Ohnishi K (1991) Reproductive and developmental toxicity studies of sparfloxacin. I. Fertility study in rats (in Japanese). Yakuri to Chiryo 19(4):1241–1255Google Scholar
  127. Tin Lee W, Collins JT (1992) Ciprofloxacin associated bilateral Achilles tendon rupture. Aust N Z J Med 22:500PubMedGoogle Scholar
  128. Tsuji A, Sato H, Kume Y, Tamai I, Okezaki E, Nagata O, Kato H (1988) Inhibitory effects of quinolone antibacterial agents on y-aminobutyric acid binding to receptor sites in the rat brain membranes. Antimicrob Agents Chemother 32:190–194PubMedGoogle Scholar
  129. Von Rosenstiel N, Adam D (1994) Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs 47:872–901CrossRefGoogle Scholar
  130. Wagai N, Tawara K (1991) Quinolone antibacterial-agent-induced cutaneous phototoxicity: ear swelling reactions. Toxicol Lett 58:215–223PubMedCrossRefGoogle Scholar
  131. Wagai N, Tawara K (1992) Possible direct role of reactive oxygens in the cause of cutaneous phototoxicity induced by five quinolones in mice. Arch Toxicol 66:392- 397PubMedCrossRefGoogle Scholar
  132. Wagai N, Yamaguchi F, Sekiguchi M, Tawara K (1990) Phototoxic potential of quinolone antibacterial agents in Balb/c mice. Toxicol Lett 54:299–308PubMedCrossRefGoogle Scholar
  133. Watanabe Y, Himi T, Saito H, Abe K (1992a) Involvement of glycin site associated with the NMDA receptor in hippocampal long-term potentiation and acquisition of spatial memory in rats. Brain Res 582:58–64PubMedCrossRefGoogle Scholar
  134. Watanabe T, Fujikawa K, Harady S, Ohura K, Sasaki T, Takayama S (1992b) Reproductive toxicity of the new quinolone antibacterial agent levofloxacin in rats and rabbits. Arzneimittelforschung 42(3A):374–377Google Scholar
  135. Williams PD, Helton DR (1991) The proconvulsive activity of quinolone antibiotics in an animal model. Toxicol Lett 58:23–28PubMedCrossRefGoogle Scholar
  136. Wolfson JS, Hooper DC (1989) Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2:378–424PubMedGoogle Scholar
  137. Yamamoto K, Naitoh Y, Inoue Y, Yoshimura K, Morikawa K, Nagata O, Hashimoto S, Yamada T, Kubo S (1988) Seizure discharges induced by the combination of a new quinolinecarboxylic acid antimicrobial drug and non-steroidal antiinflammatory drugs. Chemotherapy (Tokyo) 36(2):300–324Google Scholar
  138. Yamamura T, Kuse H, Susami M, Kawai Y, Hori M (1993) A 26-week oral toxicity study of temafloxacin in dogs. Chemotherapy (Tokyo) 41(5):214–224Google Scholar
  139. Yokota T, Kanda K (1989) Influence of new quinolones on the extension of nerve fibers in redifferentiated human neuroblastoma IMR-32 cells. Rev Infect Dis 11(5):1399–1400Google Scholar
  140. Ysern P, Clerch B, Castano M, Gibert I, Barbe J, Llagostera M (1990) Introduction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 5:63–66PubMedCrossRefGoogle Scholar
  141. Zaudig M, von Bose M, Weber MM, Bremer D, Zieglgansberger W (1989) Psychotic effects of ofloxacin. Pharmacopsychiatry 22:11–15PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • E. Von Keutz
  • W. Christ

There are no affiliations available

Personalised recommendations